MA42640B1 - Protéines de fusion de dmdv et e2 et leurs utilisations - Google Patents
Protéines de fusion de dmdv et e2 et leurs utilisationsInfo
- Publication number
- MA42640B1 MA42640B1 MA42640A MA42640A MA42640B1 MA 42640 B1 MA42640 B1 MA 42640B1 MA 42640 A MA42640 A MA 42640A MA 42640 A MA42640 A MA 42640A MA 42640 B1 MA42640 B1 MA 42640B1
- Authority
- MA
- Morocco
- Prior art keywords
- vfa
- dmdv
- fusion proteins
- relates
- vaccine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/135—Foot- and mouth-disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des compositions ou des vaccins contre le vfa. Le vaccin ou la composition peut être un vaccin ou une composition contenant des antigènes du vfa. L'invention concerne également des vecteurs recombinés codant et exprimant des antigènes, des épitopes ou des immunogènes du vfa qui peuvent être utilisés pour protéger des animaux, en particulier, des ovins, des bovins, des caprins ou des porcs, contre le vfa. L'invention concerne en outre des procédés de fabrication ou de product
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562259043P | 2015-11-23 | 2015-11-23 | |
PCT/US2016/062367 WO2017091418A1 (fr) | 2015-11-23 | 2016-11-16 | Protéines de fusion de dmdv et e2 et leurs utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
MA42640A1 MA42640A1 (fr) | 2019-05-31 |
MA42640B1 true MA42640B1 (fr) | 2021-06-30 |
Family
ID=57570585
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043310A MA43310A (fr) | 2015-11-23 | 2016-11-16 | Protéines de fusion de fmdv et e2 et leurs utilisations |
MA42640A MA42640B1 (fr) | 2015-11-23 | 2016-11-16 | Protéines de fusion de dmdv et e2 et leurs utilisations |
MA049414A MA49414A (fr) | 2015-11-23 | 2016-11-16 | Protéines de fusion de dmdv et e2 et leurs utilisations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043310A MA43310A (fr) | 2015-11-23 | 2016-11-16 | Protéines de fusion de fmdv et e2 et leurs utilisations |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049414A MA49414A (fr) | 2015-11-23 | 2016-11-16 | Protéines de fusion de dmdv et e2 et leurs utilisations |
Country Status (20)
Country | Link |
---|---|
US (2) | US9913891B2 (fr) |
EP (2) | EP3539566A1 (fr) |
JP (2) | JP6797206B2 (fr) |
KR (1) | KR102153303B1 (fr) |
CN (1) | CN108367067B (fr) |
AR (1) | AR106792A1 (fr) |
AU (1) | AU2016361305B2 (fr) |
BR (1) | BR112018010494A8 (fr) |
CA (1) | CA3006078A1 (fr) |
DK (1) | DK3380119T3 (fr) |
ES (1) | ES2899230T3 (fr) |
HK (1) | HK1258695A1 (fr) |
MA (3) | MA43310A (fr) |
MX (1) | MX2018006347A (fr) |
NZ (1) | NZ743236A (fr) |
RU (1) | RU2714428C2 (fr) |
TW (1) | TWI744260B (fr) |
UY (1) | UY36995A (fr) |
WO (1) | WO2017091418A1 (fr) |
ZA (1) | ZA201803390B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200135412A (ko) * | 2018-03-19 | 2020-12-02 | 베링거 잉겔하임 베트메디카 (차이나) 코포레이션 리미티드 | 표적 단백질을 안정적으로 발현할 수 있는 재조합 바이러스 |
CN109187993B (zh) * | 2018-09-13 | 2020-06-16 | 中国农业科学院兰州兽医研究所 | 一种口蹄疫A型病毒sIgA抗体ELISA检测试剂盒及其应用 |
CN111233984B (zh) * | 2018-11-29 | 2022-08-12 | 普莱柯生物工程股份有限公司 | 一种o型口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用 |
CN110028160B (zh) * | 2019-01-24 | 2022-04-29 | 暨南大学 | 一种功能性微藻固定化材料的制备方法及其应用 |
KR102672787B1 (ko) * | 2019-06-28 | 2024-06-05 | (주)플럼라인생명과학 | 구제역 바이러스 백신 조성물 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
CA1247080A (fr) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Sequences d'acides amines ayant une activite antigenique |
DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US4963481A (en) | 1985-12-18 | 1990-10-16 | Genetics Institute Inc | Promoter system |
DK175363B1 (da) | 1986-09-12 | 2004-09-13 | Genentech Inc | Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren |
DE3743138A1 (de) | 1987-12-18 | 1989-09-14 | Mayr Christian Gmbh & Co Kg | Schleifringlose, elektromagnetische ueberlastkupplung |
KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
EP0826063A1 (fr) | 1995-04-25 | 1998-03-04 | Vical Incorporated | Formulations en ampoule unidose de complexes adn/lipides |
US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
FR2751228B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Vaccin polynucleotidique bovin pour voie intradermique |
FR2751226B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies du cheval |
FR2751227B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
FR2751229B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
FR2751225B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
FR2751224B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs |
ES2241042T3 (es) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
CZ299473B6 (cs) | 1997-06-30 | 2008-08-06 | Rhone-Poulenc Rorer S. A. | Nukleová kyselina a elektrické pole jako sdruženýprodukt pro prenos nukleové kyseliny do bunek prícne pruhovaného svalstva |
FR2778858B1 (fr) | 1998-05-20 | 2000-06-16 | Oreal | Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique |
FR2801607B1 (fr) | 1999-11-26 | 2001-12-28 | Merial Sas | Pneumovirus du canard et vaccins correspondants |
GB9929151D0 (en) * | 1999-12-09 | 2000-02-02 | Univ Cambridge Tech | Peptide and polypeptide display |
US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
NZ545289A (en) | 2003-07-24 | 2008-05-30 | Merial Ltd | Vaccine formulations comprising an oil-in-water emulsion |
US7527960B2 (en) | 2004-06-25 | 2009-05-05 | Merial Limited | Avipox recombinants expressing foot and mouth disease virus genes |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
US20070160628A1 (en) * | 2005-08-31 | 2007-07-12 | Birkett Ashley J | Stabilized virus-like particles and epitope display systems |
WO2007108005A1 (fr) * | 2006-03-17 | 2007-09-27 | Indian Immunologicals Ltd | Particules de type tymovirus chimériques |
CN101293098A (zh) * | 2007-04-28 | 2008-10-29 | 北京迪威华宇生物技术有限公司 | 一种重组牛o型口蹄疫病毒融合蛋白疫苗 |
KR101746880B1 (ko) | 2009-09-10 | 2017-06-14 | 메리얼 인코포레이티드 | 사포닌-함유 면역보강제를 포함하는 신규 백신 제형 |
CA2792117C (fr) * | 2010-03-12 | 2016-09-20 | Merial Limited | Vaccins de recombinaison contre le virus de la fievre aphteuse et utilisations de ceux-ci |
RU2467014C2 (ru) * | 2010-12-06 | 2012-11-20 | Учреждение Российской академии наук Центр "Боинженерия" РАН | Полиэпитопный белок, нуклеотидная последовательность, кодирующая полиэпитопный белок, плазмида с последовательностью, кодирующей полиэпитопный белок, и препарат полиэпитопного белка для индукции иммунного ответа против вируса ящура |
KR20150084993A (ko) * | 2012-11-16 | 2015-07-22 | 유나이티드 바이오메디칼 인크. | 구제역 (fmd)에 대한 합성 펩티드-기재 응급 백신 |
RU2631002C2 (ru) * | 2012-12-05 | 2017-09-15 | Тевакс Дженетикс Вэксин Ко., Лтд. | Слитые белки для применения в качестве иммуногенных усиливающих агентов для индуцирования антигенспецифического т-клеточного ответа |
CN103305542B (zh) * | 2013-06-25 | 2015-03-11 | 江苏省农业科学院 | 一种重组噬菌体双表达载体及应用 |
EP3906939A1 (fr) * | 2013-10-11 | 2021-11-10 | The United States of America, represented by the Secretary, Department of Health and Human Services | Vaccins contre le virus d'epstein-barr |
CN103933581A (zh) * | 2014-05-04 | 2014-07-23 | 贵州大学 | 一种基于csf-fmd二联基因工程疫苗的制备方法 |
EP3197486A1 (fr) | 2014-09-23 | 2017-08-02 | Merial Inc. | Vaccins de recombinaison fmdv et leurs utilisations |
-
2016
- 2016-11-16 KR KR1020187017812A patent/KR102153303B1/ko active IP Right Grant
- 2016-11-16 MA MA043310A patent/MA43310A/fr unknown
- 2016-11-16 MA MA42640A patent/MA42640B1/fr unknown
- 2016-11-16 EP EP19167578.4A patent/EP3539566A1/fr active Pending
- 2016-11-16 AU AU2016361305A patent/AU2016361305B2/en not_active Ceased
- 2016-11-16 CN CN201680075080.4A patent/CN108367067B/zh active Active
- 2016-11-16 CA CA3006078A patent/CA3006078A1/fr active Pending
- 2016-11-16 ES ES16813258T patent/ES2899230T3/es active Active
- 2016-11-16 NZ NZ743236A patent/NZ743236A/en not_active IP Right Cessation
- 2016-11-16 BR BR112018010494A patent/BR112018010494A8/pt active Search and Examination
- 2016-11-16 RU RU2018122755A patent/RU2714428C2/ru active
- 2016-11-16 US US15/353,727 patent/US9913891B2/en active Active
- 2016-11-16 JP JP2018545561A patent/JP6797206B2/ja not_active Expired - Fee Related
- 2016-11-16 WO PCT/US2016/062367 patent/WO2017091418A1/fr active Application Filing
- 2016-11-16 MA MA049414A patent/MA49414A/fr unknown
- 2016-11-16 DK DK16813258.7T patent/DK3380119T3/da active
- 2016-11-16 EP EP16813258.7A patent/EP3380119B1/fr active Active
- 2016-11-16 MX MX2018006347A patent/MX2018006347A/es unknown
- 2016-11-23 AR ARP160103584A patent/AR106792A1/es unknown
- 2016-11-23 TW TW105138385A patent/TWI744260B/zh not_active IP Right Cessation
- 2016-11-23 UY UY0001036995A patent/UY36995A/es not_active Application Discontinuation
-
2018
- 2018-02-05 US US15/888,718 patent/US10363300B2/en active Active
- 2018-05-22 ZA ZA2018/03390A patent/ZA201803390B/en unknown
-
2019
- 2019-01-22 HK HK19101076.4A patent/HK1258695A1/zh unknown
-
2020
- 2020-08-06 JP JP2020133788A patent/JP2020203890A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40151B2 (fr) | Vaccins de recombinaison fmdv et leurs utilisations | |
MA42640B1 (fr) | Protéines de fusion de dmdv et e2 et leurs utilisations | |
MA43195B1 (fr) | Vaccins vectorises a adenovirus recombinants contre le virus de la fievre aphteuse (fmdv) et utilisations correspondantes | |
PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
PH12018502601A1 (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
MA40309A1 (fr) | Anticorps anti-cd73 et leurs utilisations | |
PH12017501287A1 (en) | A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist | |
PH12019500193A1 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
PH12019501973A1 (en) | Anti-phf-tau antibodies and uses thereof | |
MA34087B1 (fr) | Vaccins recombinants contre le virus de la langue bleue et leurs utilisations | |
MX2019006633A (es) | Formulaciones de anticuerpo. | |
EA035991B9 (ru) | Новый полисахарид и его применения | |
MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
NZ731571A (en) | T cell receptors | |
MX2019002903A (es) | Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos. | |
MX2017003121A (es) | Formulaciones de anticuerpos. | |
MX2020005170A (es) | Formulaciones de proteinas de fusion vegfr-fc. | |
MX2021005373A (es) | Variantes de proteinas de union al factor h y metodos de uso de estas. | |
MX2020005555A (es) | Construcciones inmunogenicas de peptidos de tau. | |
ZA201900070B (en) | Antibodies with low immunogenicity and uses thereof | |
EA201892003A1 (ru) | Лечение атопического дерматита собак | |
IN2014DN09445A (fr) | ||
MX2018013523A (es) | Anticuerpos monoclonales de adn dirigidos a il-6 y cd126. | |
MX2018011016A (es) | Formulaciones estables para liofilizar particulas terapeuticas. | |
NZ734938A (en) | Leptospira immunoprotective proteins and methods of identification and use thereof |